# Brain Dopaminergic Signaling in Opioid Use Disorders

> **NCT03190954** · EARLY_PHASE1 · COMPLETED · sponsor: **National Institute on Alcohol Abuse and Alcoholism (NIAAA)** · enrollment: 153 (actual)

## Conditions studied

- Normal Physiology
- Opioid Use Disorders

## Interventions

- **DRUG:** [11C]raclopride plus placebo
- **DRUG:** [11C]raclopride plus drug
- **DRUG:** [11C]NNC-112

## Key facts

- **NCT ID:** NCT03190954
- **Lead sponsor:** National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- **Sponsor class:** NIH
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-17
- **Primary completion:** 2025-10-27
- **Final completion:** 2025-10-27
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03190954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03190954, "Brain Dopaminergic Signaling in Opioid Use Disorders". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03190954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*